LAG3 and melanoma: Since then, additional agents targeting novel immune checkpoints, such as T-cell immunoglobulin and mucin domain containing 3 (TIM-3), lymphocyte activation gene-3 (LAG-3), and ITIM domain (TIGIT), are being investigated to expand the scope of immunotherapy for melanoma (9–11).